Potential role of hypoxia imaging using 18F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy

Monitoring Tumor Response to Carbogen Breathing by Oxygen-Sensitive Magnetic Resonance Parameters to Predict the Outcome of Radiation Therapy: A Preclinical Study

“…The lipids R 1 values obtained in this work seem less sensitive than those presented in a previous work [12]. The discrepancy could be due to different imaging acquisition sequences.…”

“…In addition, tumors were irradiated with or without hypoxia-driven intervention (carbogen) to evaluate the relation between RT outcome and MR parameters. In a previous study, it was determined by EPR oximetry and PET 18 F-FAZA that rhabdomyosarcoma and 9L-glioma had different hypoxic fractions, and, importantly, that 18 F-FAZA was able to predict the outcome of RT in those models [12]. The same protocol was used in this study to assess the predictivity of non-invasive MR parameters as to the outcome of RT.…”

Predictive value of 18F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: A preclinical study

“…For the group treated with radiation alone, a significant correlation between the T/B ratio derived from 18 F-FAZA PET images and the response of 9L-gliomas was observed (Fig. 4, top panel, r = 0.72, p = 0.0077), an observation that is consistent with the result obtained in our previous study [15]. By contrast, the response of tumors receiving RT + nimorazole was independent of the FAZA retention (Fig.…”

“…Recently, in a preclinical study [15], we provided compelling evidence that hypoxia imaging using 18 F-FAZA PET may be used as a prognostic tool for the outcome following RT and could assess the response of tumor to carbogen breathing. Based on the tumor-to-background ratio of 18 F-FAZA PET images, we were able to define the most appropriate hypoxia-driven intervention to potentiate the response to irradiation: carbogen breathing in responsive tumors or dose escalation in tumors non-responsive to carbogen.…”

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

“…Furthermore, hypoxia activated pro-drugs as TH-302 can be used to specifically target hypoxic tumours [24,25]. Hypoxia PET imaging can be used to identify tumour hypoxia and could serve as a potential predictive marker to select those patients that would benefit from these hypoxia targeting treatment regimens [26][27][28][29].…”